Gut

Papers
(The H4-Index of Gut is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms888
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19756
Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection660
Mucus barrier, mucins and gut microbiota: the expected slimy partners?628
Gut microbiome and health: mechanistic insights583
Gut microbiota-derived metabolites as central regulators in metabolic disorders464
Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries426
Interaction between drugs and the gut microbiome413
Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process359
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications339
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites338
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report302
A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice279
Global burden of oesophageal and gastric cancer by histology and subsite in 2018272
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort269
Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus265
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study257
Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake257
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome249
Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)244
SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19240
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN237
Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health231
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases225
Faecal calprotectin indicates intestinal inflammation in COVID-19222
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome219
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus213
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals213
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents213
Effect of IBD medications on COVID-19 outcomes: results from an international registry210
COVID-19 and immunomodulation in IBD209
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic205
Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis201
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD196
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome195
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19190
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis182
The role of gut microbiota in cancer treatment: friend or foe?178
Albumin in decompensated cirrhosis: new concepts and perspectives171
Advances in non-invasive assessment of hepatic fibrosis165
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis163
Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension163
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting162
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study160
Endosonography-guided gallbladder drainage versus percutaneous cholecystostomy in very high-risk surgical patients with acute cholecystitis: an international randomised multicentre controlled superior159
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm158
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19157
Guidelines on the management of ascites in cirrhosis155
COVID-19 and the gastrointestinal tract: more than meets the eye155
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology152
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial150
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores148
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching148
Calprotectin: from biomarker to biological function145
Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing144
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort144
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab142
Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients139
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups139
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community138
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications134
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility134
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis131
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning125
Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model125
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients125
Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes122
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis120
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease119
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges118
Diet quality and risk and severity of COVID-19: a prospective cohort study118
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn116
Six-month follow-up of gut microbiota richness in patients with COVID-19113
COVID-19 in an international European liver transplant recipient cohort113
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer112
Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study112
Low risk of COVID-19 transmission in GI endoscopy111
Big data in IBD: big progress for clinical practice110
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide110
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial108
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies106
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?102
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis102
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic102
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19101
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives101
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation100
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis100
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series98
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study97
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-1997
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer96
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis95
A faecal microbiota signature with high specificity for pancreatic cancer94
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma94
0.034312009811401